Literature DB >> 33141118

ALK-transformed mature T lymphocytes restore early thymus progenitor features.

Annabelle Congras1,2,3,4, Coralie Hoareau-Aveilla1,2,3,4, Nina Caillet1,2,3,4, Marie Tosolini1,2,3,5, Patrick Villarese6, Agata Cieslak6, Laura Rodriguez7, Vahid Asnafi6, Elisabeth Macintyre6, Gerda Egger8,9, Pierre Brousset1,2,3,4,10,11, Laurence Lamant1,2,3,4,10,11,12, Fabienne Meggetto1,2,3,4,6,10,11,12.   

Abstract

Anaplastic large cell lymphoma (ALCL) is a mature T cell neoplasm that often expresses the CD4+ T cell surface marker. It usually harbors the t(2;5) (p23;q35) translocation, leading to the ectopic expression of NPM-ALK, a chimeric tyrosine kinase. We demonstrated that in vitro transduction of normal human CD4+ T lymphocytes with NPM-ALK results in their immortalization and malignant transformation. The tumor cells displayed morphological and immunophenotypical characteristics of primary patient-derived anaplastic large cell lymphomas. Cell growth, proliferation, and survival were strictly dependent on NPM-ALK activity and include activation of the key factors STAT3 and DNMT1 and expression of CD30 (the hallmark of anaplastic large-cell lymphoma). Implantation of NPM-ALK-transformed CD4+ T lymphocytes into immunodeficient mice resulted in the formation of tumors indistinguishable from patients' anaplastic large cell lymphomas. Integration of "Omic" data revealed that NPM-ALK-transformed CD4+ T lymphocytes and primary NPM-ALK+ ALCL biopsies share similarities with early T cell precursors. Of note, these NPM-ALK+ lymphoma cells overexpress stem cell regulators (OCT4, SOX2, and NANOG) and HIF2A, which is known to affect hematopoietic precursor differentiation and NPM-ALK+ cell growth. Altogether, for the first time our findings suggest that NPM-ALK could restore progenitor-like features in mature CD30+ peripheral CD4+ T cells, in keeping with a thymic progenitor-like pattern.

Entities:  

Keywords:  Epigenetics; Hematology; Lymphomas; T cells

Year:  2020        PMID: 33141118      PMCID: PMC7685726          DOI: 10.1172/JCI134990

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

Review 1.  Transcriptional and Epigenetic Control of Regulatory T Cell Development.

Authors:  Yohko Kitagawa; James Badger Wing; Shimon Sakaguchi
Journal:  Prog Mol Biol Transl Sci       Date:  2015-08-19       Impact factor: 3.622

2.  The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.

Authors:  Qian Zhang; Fang Wei; Hong Yi Wang; Xiaobin Liu; Darshan Roy; Qun-Bin Xiong; Shuguang Jiang; Andrew Medvec; Gwenn Danet-Desnoyers; Christopher Watt; Ewa Tomczak; Michael Kalos; James L Riley; Mariusz A Wasik
Journal:  Am J Pathol       Date:  2013-12       Impact factor: 4.307

3.  CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells.

Authors:  T M Ellis; P E Simms; D J Slivnick; H M Jäck; R I Fisher
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

4.  Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin.

Authors:  N Moti; T Malcolm; R Hamoudi; S Mian; G Garland; C E Hook; G A A Burke; M A Wasik; O Merkel; L Kenner; E Laurenti; J E Dick; S D Turner
Journal:  Oncogene       Date:  2014-05-12       Impact factor: 9.867

5.  CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.

Authors:  Bettina Bisig; Aurélien de Reyniès; Christophe Bonnet; Pierre Sujobert; David S Rickman; Teresa Marafioti; Georges Delsol; Laurence Lamant; Philippe Gaulard; Laurence de Leval
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

6.  New avenues for targeted therapies and biomarkers in anaplastic large cell lymphoma.

Authors:  Gerda Egger; Suzanne D Turner
Journal:  Epigenomics       Date:  2017-01-18       Impact factor: 4.778

Review 7.  ALK-positive anaplastic large cell lymphoma: an evolving story.

Authors:  Irina Bonzheim; Julia Steinhilber; Falko Fend; Laurence Lamant; Leticia Quintanilla-Martinez
Journal:  Front Biosci (Schol Ed)       Date:  2015-06-01

8.  Charting a dynamic DNA methylation landscape of the human genome.

Authors:  Michael J Ziller; Hongcang Gu; Fabian Müller; Julie Donaghey; Linus T-Y Tsai; Oliver Kohlbacher; Philip L De Jager; Evan D Rosen; David A Bennett; Bradley E Bernstein; Andreas Gnirke; Alexander Meissner
Journal:  Nature       Date:  2013-08-07       Impact factor: 49.962

9.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

10.  Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress.

Authors:  Tim I M Malcolm; Patrick Villarese; Camilla J Fairbairn; Laurence Lamant; Amélie Trinquand; C Elizabeth Hook; G A Amos Burke; Laurence Brugières; Katherine Hughes; Dominique Payet; Olaf Merkel; Ana-Iris Schiefer; Ibraheem Ashankyty; Shahid Mian; Mariusz Wasik; Martin Turner; Lukas Kenner; Vahid Asnafi; Elizabeth Macintyre; Suzanne D Turner
Journal:  Nat Commun       Date:  2016-01-12       Impact factor: 14.919

View more
  7 in total

1.  Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK-driven lymphomagenesis.

Authors:  Elisa Redl; Raheleh Sheibani-Tezerji; Crhistian de Jesus Cardona; Patricia Hamminger; Gerald Timelthaler; Melanie Rosalia Hassler; Maša Zrimšek; Sabine Lagger; Thomas Dillinger; Lorena Hofbauer; Kristina Draganić; Andreas Tiefenbacher; Michael Kothmayer; Charles H Dietz; Bernard H Ramsahoye; Lukas Kenner; Christoph Bock; Christian Seiser; Wilfried Ellmeier; Gabriele Schweikert; Gerda Egger
Journal:  Life Sci Alliance       Date:  2020-12-11

Review 2.  NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target.

Authors:  Elissa Andraos; Joséphine Dignac; Fabienne Meggetto
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639

3.  Identification and Characterization of Alcohol-related Hepatocellular Carcinoma Prognostic Subtypes based on an Integrative N6-methyladenosine methylation Model.

Authors:  Yue Zhang; Fanhong Zeng; Min Zeng; Xu Han; Lei Cai; Jiajun Zhang; Jun Weng; Yi Gao
Journal:  Int J Biol Sci       Date:  2021-08-14       Impact factor: 6.580

Review 4.  Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Authors:  Lucy Hare; G A Amos Burke; Suzanne D Turner
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639

5.  De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.

Authors:  Loélia Babin; Alice Darchen; Elie Robert; Zakia Aid; Rosalie Borry; Claire Soudais; Marion Piganeau; Anne De Cian; Carine Giovannangeli; Olivia Bawa; Charlotte Rigaud; Jean-Yves Scoazec; Lucile Couronné; Layla Veleanu; Agata Cieslak; Vahid Asnafi; David Sibon; Laurence Lamant; Fabienne Meggetto; Thomas Mercher; Erika Brunet
Journal:  Mol Cancer       Date:  2022-03-04       Impact factor: 27.401

6.  Clonotype pattern in T-cell lymphomas map the cell of origin to immature lymphoid precursors.

Authors:  Aishwarya Iyer; Dylan Hennessey; Robert Gniadecki
Journal:  Blood Adv       Date:  2022-04-12

Review 7.  Anaplastic lymphoma kinase-special immunity and immunotherapy.

Authors:  Ye Guo; Hanfei Guo; Yongfei Zhang; Jiuwei Cui
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.